Myocardial clearance kinetics of technetium-99m-teboroxime following dipyridamole: differentiation of stenosis severity in canine myocardium
- PMID: 7799062
Myocardial clearance kinetics of technetium-99m-teboroxime following dipyridamole: differentiation of stenosis severity in canine myocardium
Abstract
The purpose of the current study was to determine whether teboroxime clearance kinetics are useful in differentiating the severity of coronary artery flow restriction.
Methods: Groups of dogs received stenoses of the left circumflex coronary artery as follows: nine dogs received a mild-to-moderate stenosis (Group 2) and eleven dogs received severe stenoses (Group 3). In three control dogs (Group 1), there was no stenosis. Using miniature cadmium-telluride radiation detectors, myocardial teboroxime activities were continuously monitored in both the control and stenosed zones following dipyridamole infusion.
Results: A significant difference in fractional myocardial clearance between the control zones (0.69 +/- 0.01, n = 26) versus mild-to-moderate (0.61 +/- 0.06, p < 0.05, n = 9) and severe (0.57 +/- 0.03, p < 0.01 versus control, p < 0.05 versus mild-to-moderate, n = 11) flow-restricted zones was observed over a 1-hr period. Significant differences between normal and both stenosed zones became apparent after 7 min of clearance. Significant differences in myocardial clearance between mild-to-moderate and severe groups were detected within 15 min.
Conclusion: Thus, in this canine model using dipyridamole, miniature probe-determined teboroxime myocardial clearance can differentiate among normal myocardium, myocardium distal to a mild-to-moderate stenosis and myocardium distal to a severe stenosis.
Comment in
-
Myocardial clearance kinetics of technetium-99m-teboroxime following dipyridamole injection.J Nucl Med. 1995 Jan;36(1):119-20. J Nucl Med. 1995. PMID: 7799063 No abstract available.
Similar articles
-
Myocardial technetium 99m-labeled teboroxime clearance derived from canine scans differentiates severity of stenosis after dipyridamole.J Nucl Cardiol. 1994 Jul-Aug;1(4):338-50. doi: 10.1007/BF02939955. J Nucl Cardiol. 1994. PMID: 9420717
-
Early myocardial clearance kinetics of technetium-99m-teboroxime differentiate normal and flow-restricted canine myocardium at rest.J Nucl Med. 1993 Apr;34(4):630-6. J Nucl Med. 1993. PMID: 8455080
-
Myocardial clearance kinetics of technetium-99m-teboroxime following dipyridamole injection.J Nucl Med. 1995 Jan;36(1):119-20. J Nucl Med. 1995. PMID: 7799063 No abstract available.
-
Advances in myocardial perfusion imaging: 99mTc-teboroxime.J Nucl Biol Med (1991). 1992 Apr-Jun;36(2 Suppl):22-8. J Nucl Biol Med (1991). 1992. PMID: 1450239 Review. No abstract available.
-
Physiologic properties of myocardial perfusion tracers.Cardiol Clin. 1994 May;12(2):169-85. Cardiol Clin. 1994. PMID: 8033171 Review.
Cited by
-
Technetium 99m-N-NOET: although not equivalent to thallium-201, it still offers new opportunities.J Nucl Cardiol. 2000 Mar-Apr;7(2):185-8. doi: 10.1016/s1071-3581(00)90043-6. J Nucl Cardiol. 2000. PMID: 10796010 No abstract available.
-
Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.EJNMMI Res. 2014 Aug 1;4:42. doi: 10.1186/s13550-014-0042-6. eCollection 2014. EJNMMI Res. 2014. PMID: 25411652 Free PMC article.
-
Planar imaging of 99mTc-labeled (bis(N-ethoxy, N-ethyl dithiocarbamato) nitrido technetium[V]) can detect resting ischemia.J Nucl Cardiol. 1997 May-Jun;4(3):217-25. doi: 10.1016/s1071-3581(97)90082-9. J Nucl Cardiol. 1997. PMID: 9199259
MeSH terms
Substances
LinkOut - more resources
Full Text Sources